View Older Stories View More Recent Stories
-
Hims & Hers Health, Inc. (HIMS) on Watch; Novo Nordisk (NVO) Expands Legal Action to Protect US Patients From Non-FDA-approved Compounded 'Semaglutide'
-
UBS Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Neutral
-
Barclays on GLP-1s: 'we caution that price erosion across GLP-1 class could come faster and more deeply than we expected'
-
UBS' Quality and Growth Opportunities Screener yields 15 stocks
-
Novo Nordisk (NVO) stock: Where next after profit warning?
-
Novo Nordisk shares hit lowest level in over 3-years
-
Trump admin to pilot coverage of weight‑loss drugs under Medicare and Medicaid - WaPo
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
HSBC Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Hold
-
BofA Securities Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Neutral
-
Barclays Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Equalweight
-
Novo Nordisk (NVO) PT Lowered to $55 at BMO Capital
-
Active options: NVDA SOFI AMD TSLA UNH SMCI OPEN PYPL NVO
-
Novo Nordisk cuts full-year sales and profit guidance, stock plunges
-
Novo Nordisk (NVO) appoints Maziar Mike Doustdar as CEO and President, Chief Scientific Officer Retires
-
Hims & Hers (HIMS) reportedly makes statement on congressional letter to FDA
-
Hims & Hers Health, Inc. (NYSE: HIMS) Falls, Group Of 81 Bipartisan Lawmakers Sign Letter On Glp-1 Action
-
Deutsche Bank Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Hims & Hers (HIMS) launches ads targeting patient personalization in newspapers
-
Novo Nordisk (NVO): New Wegovy dose submitted to European Medicines Agency for approval
-
Morgan Stanley on Compounder Lawsuits: 'experts think the courts would likely refuse to dismiss the case and that it could take 2-3 years to resolve'
-
WeightWatchers (WGHTQ) and Novo Nordisk (NVO) Expand Collaboration to Improve Medication Access Through Trusted, Holistic Model of Care
-
LifeMD (LFMD) stock rises on continued Wegovy partnership with Novo Nordisk (NVO)
-
Novo Nordisk (NVO) continues efforts to support patient access to authentic, FDA approved Wegovy and prioritize patient safety
-
Chardan Comments on iBio, Inc. (IBIO)
-
Novo Resources (NVO) announces AGM voting results
-
Deutsche Bank Reiterates Hold Rating on Hims and Hers (HIMS)
-
Novo Nordisk (NVO): Ozempic receives EU recommendation in peripheral arterial disease
-
Morgan Stanley Reiterates Equalweight Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Hims & Hers (HIMS) CEO responds to Novo Nordisk (NVO) news
-
Morgan Stanley on Hims and Hers (HIMS): 'The abrupt change could renew concerns over litigation'
-
Novo Nordisk (NVO) terminates collaboration with Hims & Hers Health (HIMS) due to concerns about their illegal mass compounding and deceptive marketing
-
Hims & Hers stock falls after Novo Nordisk ends weight loss drug pact
-
Hims & Hers Health, Inc. (HIMS) Falls 18% After Pact with Novo Nordisk Ends
-
GLP-1s Should Be First Line To Prevent Heart Disease, Acc Says - Bloomberg
-
TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO) Following Management Meeting
-
Novo Nordisk (NVO) to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
-
Sens. Sanders and King Co-Sponsor Bill to End Pharma Ads to Consumers -- WSJ
-
NVIDIA (NVDA) Partners With Novo Nordisk and DCAI to Advance Drug Discovery
-
Activist Hedge Fund Parvus Asset Management is Building a Stake in Novo Nordisk (NVO) - FT
-
EMA says Ozempic, Wegovy may cause rare eye condition
-
Citi Drops Third Note on Hims and Hers (HIMS) Inside 20 Hours: 'HIMS is now offering discounts on its bundles, effectively passing through the price discount'
-
Hims & Hers Health: Analysts remain bearish
-
LifeMD, Inc. (LFMD) Collaborates with Novo Nordisk to Launch $299 Introductory Bundle for Self-Pay Patients Prescribed Wegovy
-
New Novo Nordisk (NVO) initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect
-
Takeaways from UBS's 2025 Healthcare Insurance Symposium
-
BMO Capital on Novo Nordisk (NVO): 'CEO Switch Up Highlights Recent Novo Pressures'
-
Novo Nordisk (NVO): Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk
-
BMO Capital Reiterates Market Perform Rating on Novo Nordisk (NVO)
-
Septerna (SEPN) and Novo Nordisk (NVO) to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
